GE HealthCare Expands Into Radiopharma with $945M Sofie Acquisition Amid Margin Reset

What happened

GE HealthCare Technologies announced an agreement to acquire Sofie Biosciences for approximately $945 million, marking a push into radiopharmaceutical therapies beyond its existing diagnostic imaging portfolio. The deal arrives while GEHC is still absorbing tariff-driven margin compression—Q1’26 adjusted EBIT margin fell to 13.5% from 15.0%—and integrating the $2.3 billion Intelerad software acquisition, so management is layering another large integration onto an already stressed P&L. Sofie adds growth in a lucrative area, but the company has not yet demonstrated acquisition ROI; no Intelerad adoption KPIs have been disclosed and the first Advanced Imaging Solutions (AIS) recast reporting is still pending. The cash outlay will increase net debt from $5,491 million (1.4x EBITDA) and reduce flexibility just as tariffs already cut Q1’26 cash flow by roughly $110 million. The purchase does not address the near-term margin-reset risk, so the stock’s WAIT rating remains appropriate until management proves it can execute multiple integrations while holding FY2026 adjusted EBIT margin at 15.4%–15.7%.

Implication

The $945 million deal likely pressures FY2026 free cash flow and net debt, with minimal contribution to the 2026 adjusted EBIT margin band of 15.4%–15.7%, leaving the primary downside trigger—a guidance cut—unchanged. Sofie's radiopharmaceutical pipeline may not generate meaningful revenue for years, making this an expensive option rather than an accretive bolt-on. Management's decision to pursue another large acquisition after cutting profit guidance and stating tariffs cannot be fully offset suggests a bias toward growth over margin defense, which could delay the earnings recovery. The market should demand concrete milestones—FDA approvals, revenue contributions, or segment margins—rather than fluffy commentary about market size before crediting the deal. Until AIS recast reporting and Intelerad KPIs demonstrate integration competence, GEHC's risk-reward remains unfavorable above the $68–$70 zone, and the attractive entry near $58 still applies.

Thesis delta

The previous thesis already called for waiting for margin evidence, and this acquisition does not upgrade it. The Sofie purchase extends strategic reach into radiopharma but increases integration and capital allocation risk while tariffs compress margins. The rating remains WAIT, with the onus on management to show near-term profitability discipline before the stock earns a higher multiple.